Iron metabolism and the role of the iron-regulating hormone hepcidin in health and disease

Presse Medicale

Volumn 46, Issue 12P2, 2017, Pages e272-e278

  Daher, Raed ^a   Manceau, Hana ^a   Karim, Zoubida ^a  

^a Sorbonne University in Paris   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPCIDIN; IRON;

ANEMIA; BLOOD TRANSFUSION; ERYTHROPOIESIS; GENE MUTATION; GLUCONEOGENESIS; HEMOCHROMATOSIS; HEMOSIDEROSIS; HEREDITARY HEMOCHROMATOSIS; HUMAN; IRON ABSORPTION; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; METABOLIC REGULATION; METABOLIC SYNDROME X; NONHUMAN; OXIDATIVE STRESS; SHORT SURVEY; METABOLISM; PHYSIOLOGY;

HEMOCHROMATOSIS; HEPCIDINS; HUMANS; IRON; IRON OVERLOAD;

EID: 85033402678     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2017.10.006     Document Type: Short Survey

References (71)

1. Aisen, P., Enns, C., Wessling-Resnick, M., Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol 33 (2001), 940–959.
2. Chung, J., Wessling-Resnick, M., Molecular mechanisms and regulation of iron transport. Crit Rev Clin Lab Sci 40 (2003), 151–182, 10.1080/713609332.
3. McKie, A.T., Barrow, D., Latunde-Dada, G.O., Rolfs, A., Sager, G., Mudaly, E., et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 291 (2001), 1755–1759, 10.1126/science.1057206.
4. Shayeghi, M., Latunde-Dada, G.O., Oakhill, J.S., Laftah, A.H., Takeuchi, K., Halliday, N., et al. Identification of an intestinal heme transporter. Cell 122 (2005), 789–801, 10.1016/j.cell.2005.06.025.
5. Abboud, S., Haile, D.J., A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 275 (2000), 19906–19912, 10.1074/jbc.M000713200.
6. McKie, A.T., Marciani, P., Rolfs, A., Brennan, K., Wehr, K., Barrow, D., et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 5 (2000), 299–309.
7. Vulpe, C.D., Kuo, Y.M., Murphy, T.L., Cowley, L., Askwith, C., Libina, N., et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 21 (1999), 195–199, 10.1038/5979.
8. Morgan, E.H., Transferrin, biochemistry, physiology and clinical significance. Mol Aspects Med 4 (1981), 1–123, 10.1016/0098-2997(81)90003-0.
9. Ohgami, R.S., Campagna, D.R., Greer, E.L., Antiochos, B., McDonald, A., Chen, J., et al. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet 37 (2005), 1264–1269, 10.1038/ng1658.
10. Pigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276 (2001), 7811–7819, 10.1074/jbc.M008923200.
11. Nicolas, G., Bennoun, M., Devaux, I., Beaumont, C., Grandchamp, B., Kahn, A., et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 98 (2001), 8780–8785, 10.1073/pnas.151179498.
12. Lesbordes-Brion, J.-C., Viatte, L., Bennoun, M., Lou, D.-Q., Ramey, G., Houbron, C., et al. Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood 108 (2006), 1402–1405, 10.1182/blood-2006-02-003376.
13. Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A., Ward, D.M., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004), 2090–2093, 10.1126/science.1104742.
14. Delaby, C., Pilard, N., Gonçalves, A.S., Beaumont, C., Canonne-Hergaux, F., Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood 106 (2005), 3979–3984, 10.1182/blood-2005-06-2398.
15. Mena, N.P., Esparza, A., Tapia, V., Valdés, P., Núñez, M.T., Hepcidin inhibits apical iron uptake in intestinal cells. Am J Physiol Gastrointest Liver Physiol 294 (2008), G192–G198, 10.1152/ajpgi.00122.2007.
16. Chaston, T., Chung, B., Mascarenhas, M., Marks, J., Patel, B., Srai, S.K., et al. Evidence for differential effects of hepcidin in macrophages and intestinal epithelial cells. Gut 57 (2008), 374–382, 10.1136/gut.2007.131722.
17. Brasse-Lagnel, C., Karim, Z., Letteron, P., Bekri, S., Bado, A., Beaumont, C., Intestinal DMT1 cotransporter is down-regulated by hepcidin via proteasome internalization and degradation. Gastroenterology 140 (2011), 1261e1–1271e1, 10.1053/j.gastro.2010.12.037.
18. Foot, N.J., Leong, Y.A., Dorstyn, L.E., Dalton, H.E., Ho, K., Zhao, L., et al. Ndfip1-deficient mice have impaired DMT1 regulation and iron homeostasis. Blood 117 (2011), 638–646, 10.1182/blood-2010-07-295287.
19. Ganz, T., Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102 (2003), 783–788, 10.1182/blood-2003-03-0672.
20. Origa, R., Galanello, R., Ganz, T., Giagu, N., Maccioni, L., Faa, G., et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 92 (2007), 583–588.
21. Babitt, J.L., Huang, F.W., Wrighting, D.M., Xia, Y., Sidis, Y., Samad, T.A., et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38 (2006), 531–539, 10.1038/ng1777.
22. Meynard, D., Kautz, L., Darnaud, V., Canonne-Hergaux, F., Coppin, H., Roth, M.-P., Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 41 (2009), 478–481, 10.1038/ng.320.
23. Corradini, E., Meynard, D., Wu, Q., Chen, S., Ventura, P., Pietrangelo, A., et al. Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology 54 (2011), 273–284, 10.1002/hep.24359.
24. Corradini, E., Babitt, J.L., Lin, H.Y., The RGM/DRAGON family of BMP co-receptors. Cytokine Growth Factor Rev 20 (2009), 389–398, 10.1016/j.cytogfr.2009.10.008.
25. Chen, J., Chloupková, M., Gao, J., Chapman-Arvedson, T.L., Enns, C.A., HFE modulates transferrin receptor 2 levels in hepatoma cells via interactions that differ from transferrin receptor 1-HFE interactions. J Biol Chem 282 (2007), 36862–36870, 10.1074/jbc.M706720200.
26. D'Alessio, F., Hentze, M.W., Muckenthaler, M.U., The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation. J Hepatol 57 (2012), 1052–1060, 10.1016/j.jhep.2012.06.015.
27. Zhang, A.-S., Anderson, S.A., Wang, J., Yang, F., DeMaster, K., Ahmed, R., et al. Suppression of hepatic hepcidin expression in response to acute iron deprivation is associated with an increase of matriptase-2 protein. Blood 117 (2011), 1687–1699, 10.1182/blood-2010-06-287292.
28. De Falco, L., Sanchez, M., Silvestri, L., Kannengiesser, C., Muckenthaler, M.U., Iolascon, A., et al. Iron refractory iron deficiency anemia. Haematologica 98 (2013), 845–853, 10.3324/haematol.2012.075515.
29. Du, X., She, E., Gelbart, T., Truksa, J., Lee, P., Xia, Y., et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science 320 (2008), 1088–1092, 10.1126/science.1157121.
30. Silvestri, L., Pagani, A., Nai, A., De Domenico, I., Kaplan, J., Camaschella, C., The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 8 (2008), 502–511, 10.1016/j.cmet.2008.09.012.
31. Guillem, F., Kannengiesser, C., Oudin, C., Lenoir, A., Matak, P., Donadieu, J., et al. Inactive matriptase-2 mutants found in IRIDA patients still repress hepcidin in a transfection assay despite having lost their serine protease activity. Hum Mutat 33 (2012), 1388–1396, 10.1002/humu.22116.
32. Peyssonnaux, C., Zinkernagel, A.S., Schuepbach, R.A., Rankin, E., Vaulont, S., Haase, V.H., et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 117 (2007), 1926–1932, 10.1172/JCI31370.
33. Casanovas, G., Spasić, M.V., Casu, C., Rivella, S., Strelau, J., Unsicker, K., et al. The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica 98 (2013), 444–447, 10.3324/haematol.2012.069807.
34. Kautz, L., Jung, G., Valore, E.V., Rivella, S., Nemeth, E., Ganz, T., Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 46 (2014), 678–684, 10.1038/ng.2996.
35. Seldin, M.M., Peterson, J.M., Byerly, M.S., Wei, Z., Wong, G.W., Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem 287 (2012), 11968–11980, 10.1074/jbc.M111.336834.
36. Nai, A., Rubio, A., Campanella, A., Gourbeyre, O., Artuso, I., Bordini, J., et al. Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice. Blood 127 (2016), 2327–2336, 10.1182/blood-2015-11-681494.
37. Wang, C.-Y., Core, A.B., Canali, S., Zumbrennen-Bullough, K.B., Ozer, S., Umans, L., et al. Smad1/5 is required for erythropoietin-mediated suppression of hepcidin in mice. Blood 130 (2017), 73–83.
38. Aschemeyer, S., Gabayan, V., Ganz, T., Nemeth, E., Kautz, L., Erythroferrone and matriptase-2 independently regulate hepcidin expression. Am J Hematol 92 (2017), E61–E63, 10.1002/ajh.24672.
39. Andrews, N.C., Disorders of iron metabolism. N Engl J Med 341 (1999), 1986–1995, 10.1056/NEJM199912233412607.
40. Hershko, C., Graham, G., Bates, G.W., Rachmilewitz, E.A., Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 40 (1978), 255–263.
41. Brissot, P., Ropert, M., Le Lan, C., Loréal, O., Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 1820 (2012), 403–410, 10.1016/j.bbagen.2011.07.014.
42. Craven, C.M., Alexander, J., Eldridge, M., Kushner, J.P., Bernstein, S., Kaplan, J., Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypotransferrinemic mouse: a rodent model for hemochromatosis. Proc Natl Acad Sci U S A 84 (1987), 3457–3461.
43. Jenkitkasemwong, S., Wang, C.-Y., Coffey, R., Zhang, W., Chan, A., Biel, T., et al. SLC39A14 is required for the development of hepatocellular iron overload in murine models of hereditary hemochromatosis. Cell Metab 22 (2015), 138–150, 10.1016/j.cmet.2015.05.002.
44. Pinilla-Tenas, J.J., Sparkman, B.K., Shawki, A., Illing, A.C., Mitchell, C.J., Zhao, N., et al. Zip14 is a complex broad-scope metal-ion transporter whose functional properties support roles in the cellular uptake of zinc and nontransferrin-bound iron. Am J Physiol Cell Physiol 301 (2011), C862–C871, 10.1152/ajpcell.00479.2010.
45. Nam, H., Wang, C.-Y., Zhang, L., Zhang, W., Hojyo, S., Fukada, T., et al. ZIP14 and DMT1 in the liver, pancreas, and heart are differentially regulated by iron deficiency and overload: implications for tissue iron uptake in iron-related disorders. Haematologica 98 (2013), 1049–1057, 10.3324/haematol.2012.072314.
46. Oudit, G.Y., Sun, H., Trivieri, M.G., Koch, S.E., Dawood, F., Ackerley, C., et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 9 (2003), 1187–1194, 10.1038/nm920.
47. 2+ influx. Mol Pharmacol 82 (2012), 1194–1204, 10.1124/mol.112.080184.
48. Fernandes, J.L., Sampaio, E.F., Fertrin, K., Coelho, O.R., Loggetto, S., Piga, A., et al. Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. Am J Med 126 (2013), 834–837, 10.1016/j.amjmed.2013.05.002.
49. Sugishita, K., Asakawa, M., Usui, S., Takahashi, T., A case of iron overload cardiomyopathy: beneficial effects of iron chelating agent and calcium channel blocker on left ventricular dysfunction. Int Heart J 50 (2009), 829–838.
50. Feder, J.N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D.A., Basava, A., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13 (1996), 399–408, 10.1038/ng0896-399.
51. Feder, J.N., Penny, D.M., Irrinki, A., Lee, V.K., Lebrón, J.A., Watson, N., et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A 95 (1998), 1472–1477.
52. Bacon, B.R., Britton, R.S., Clinical penetrance of hereditary hemochromatosis. N Engl J Med 358 (2008), 291–292, 10.1056/NEJMe078215.
53. Deugnier, Y., Mosser, J., Modifying factors of the HFE hemochromatosis phenotype. Expert Rev Gastroenterol Hepatol 2 (2008), 531–540, 10.1586/17474124.2.4.531.
54. Papanikolaou, G., Samuels, M.E., Ludwig, E.H., MacDonald, M.L.E., Franchini, P.L., Dubé, M.-P., et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 36 (2004), 77–82, 10.1038/ng1274.
55. Roetto, A., Papanikolaou, G., Politou, M., Alberti, F., Girelli, D., Christakis, J., et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 33 (2003), 21–22, 10.1038/ng1053.
56. Camaschella, C., Roetto, A., Calì, A., De Gobbi, M., Garozzo, G., Carella, M., et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 25 (2000), 14–15, 10.1038/75534.
57. Wallace, D.F., Clark, R.M., Harley, H.A.J., Subramaniam, V.N., Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis. J Hepatol 40 (2004), 710–713, 10.1016/j.jhep.2003.12.008.
58. Sham, R.L., Phatak, P.D., West, C., Lee, P., Andrews, C., Beutler, E., Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis 34 (2005), 157–161, 10.1016/j.bcmd.2004.12.002.
59. Daher, R., Kannengiesser, C., Houamel, D., Lefebvre, T., Bardou-Jacquet, E., Ducrot, N., et al. Heterozygous mutations in BMP6 pro-peptide lead to inappropriate hepcidin synthesis and moderate iron overload in humans. Gastroenterology 150 (2016), 672e4–683e4, 10.1053/j.gastro.2015.10.049.
60. Le Gac, G., Gourlaouen, I., Ka, C., Férec, C., The p.Leu96Pro missense mutation in the BMP6 gene is repeatedly associated with hyperferritinemia in patients of French origin. Gastroenterology 151 (2016), 769–770, 10.1053/j.gastro.2016.03.054.
61. Bignell, P., Atoyebi, W., Robson, K., Heterozygous BMP6 variants coupled with HFE variants. Gastroenterology, 151, 2016, 769, 10.1053/j.gastro.2016.02.088.
62. Camaschella, C., Nai, A., Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Br J Haematol 172 (2016), 512–523, 10.1111/bjh.13820.
63. Borgna-Pignatti, C., Cappellini, M.D., De Stefano, P., Del Vecchio, G.C., Forni, G.L., Gamberini, M.R., et al. Survival and complications in thalassemia. Ann N Y Acad Sci 1054 (2005), 40–47, 10.1196/annals.1345.006.
64. Pinto, V., Balocco, M., Ambaglio, I., Derchi, G., Malcovati, L., Forni, G.L., Iron overload-related heart failure in a patient with transfusion-dependent myelodysplastic syndrome reversed by intensive combined chelation therapy. Clin Case Rep 3 (2015), 952–954, 10.1002/ccr3.407.
65. Shenoy, N., Vallumsetla, N., Rachmilewitz, E., Verma, A., Ginzburg, Y., Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood 124 (2014), 873–881, 10.1182/blood-2014-03-563221.
66. Rose, C., Brechignac, S., Vassilief, D., Pascal, L., Stamatoullas, A., Guerci, A., et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe francophone des myélodysplasies). Leuk Res 34 (2010), 864–870, 10.1016/j.leukres.2009.12.004.
67. Vichinsky, E., Butensky, E., Fung, E., Hudes, M., Theil, E., Ferrell, L., et al. Comparison of organ dysfunction in transfused patients with SCD or beta-thalassemia. Am J Hematol 80 (2005), 70–74, 10.1002/ajh.20402.
68. Meloni, A., Puliyel, M., Pepe, A., Berdoukas, V., Coates, T.D., Wood, J.C., Cardiac iron overload in sickle-cell disease. Am J Hematol 89 (2014), 678–683, 10.1002/ajh.23721.
69. Porter, J.B., Walter, P.B., Neumayr, L.D., Evans, P., Bansal, S., Garbowski, M., et al. Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients. Br J Haematol 167 (2014), 692–696, 10.1111/bjh.13081.
70. de Montalembert, M., Ribeil, J.-A., Brousse, V., Guerci-Bresler, A., Stamatoullas, A., Vannier, J.-P., et al. Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome. PloS One, 12, 2017, e0172147, 10.1371/journal.pone.0172147.
71. Deugnier, Y., Lainé, F., [Dysmetabolic iron overload syndrome: a systemic disease?]. Presse Med 43 (2014), 625–627, 10.1016/j.lpm.2014.03.008.